Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Panacos Pharmaceuticals, Inc. (PANC)
Watertown, US
Panacos Pharmaceuticals, Inc. functions as an early-stage biotechnology firm specializing in the research and development of orally administered small-molecule therapeutics. These innovative drugs are crafted to combat human immunodeficiency virus (HIV) and various other viral diseases affecting humans. The company's scientific methodology concentrates on identifying novel targets within the viral life cycle, specifically focusing on processes like virus maturation and fusion. Currently, their product portfolio includes advanced initiatives, such as second- and third-generation programs, centered on inhibiting HIV maturation. Founded in 1999, the company's main operations are situated in Watertown, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -95.00% | +9,900.00% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-36.6% Q3'08: -20.0% (vs Q3'07)
-
EPS growth Biotechnology: +29.7%+6.7% Q3'08: +0.0% (vs Q3'07)
-
FCF margin FCF growth · Biotechnology: +16.2%-20,782.2% Q3'08: -32,508.3% (vs Q3'07)
-
EBIT margin Biotechnology: +0.0%-21,678.9% Q3'08: -31,545.8% (vs Q3'07)
-
ROIC Biotechnology: -16.1%—
-
Share dilution Biotechnology: -3.4%+5.2% Q3'08: +0.3% (vs Q3'07)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.51× Q3'08: -0.63× (vs Q3'07)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2008 actual |
Dec 2009 actual |
|---|---|---|
| Revenue |
120.0K
est.
|
140.0K
est.
|
| EBITDA |
-120.0K
est.
|
-140.0K
est.
|
| EBIT |
-120.0K
est.
|
-140.0K
est.
|
| Net Income |
—
est.
|
—
est.
|
| SGA |
3.43M
est.
|
4.00M
est.
|
| EPS |
—
est.
|
—
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008-06-19 | Savage Robert G. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.59 | 8.9K | 15,000 | — | ↗ |
| 2008-06-19 | LIMBER JOSEPH M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.59 | 8.9K | 15,000 | — | ↗ |
| 2008-06-19 | LERNER IRWIN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.59 | 8.9K | 15,000 | — | ↗ |
| 2008-06-19 | Fischer Laurent | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.59 | 8.9K | 15,000 | — | ↗ |
| 2008-06-19 | FLETCHER R JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.59 | 8.9K | 15,000 | — | ↗ |
| 2008-04-30 | DUNTON ALAN W | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 0.46 | 46.2K | 240,865 | — | ↗ |
| 2008-02-13 | DUNTON ALAN W | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 37,500 | 3.00 | 112.5K | 37,500 | — | ↗ |
| 2007-12-18 | DUNTON ALAN W | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 140,865 | — | ↗ |
| 2007-12-14 | DUNTON ALAN W | Director / Officer | P-Purchase | A | Common Stock | 30,865 | 0.81 | 25.0K | 40,865 | — | ↗ |
| 2007-08-03 | DUNTON ALAN W | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.51 | 25.1K | 10,000 | — | ↗ |
| 2007-06-12 | SAVAGE ROBERT G | Director | A-Award | A | Right to Buy (Stock Option) | 15,000 | 3.92 | 58.8K | 15,000 | — | ↗ |
| 2007-06-12 | LIMBER JOSEPH M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 8.27 | 124.1K | 15,000 | — | ↗ |
| 2007-06-12 | LERNER IRWIN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 8.27 | 124.1K | 15,000 | — | ↗ |
| 2007-06-12 | Fischer Laurent | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 3.92 | 29.4K | 7,500 | — | ↗ |
| 2007-06-12 | FLETCHER R JOHN | Director | A-Award | A | Stock options (right to buy) | 15,000 | 8.27 | 124.1K | 15,000 | — | ↗ |
| 2007-04-13 | SAVAGE ROBERT G | Director | A-Award | A | Right to Buy (Stock Option) | 25,000 | 4.67 | 116.8K | 25,000 | — | ↗ |
| 2007-01-24 | LIMBER JOSEPH M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2007-01-24 | LERNER IRWIN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2007-01-24 | Fischer Laurent | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2007-01-24 | FLETCHER R JOHN | Director | A-Award | A | Stock Options (Right to Buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2007-01-05 | DUNTON ALAN W | Director / Officer | A-Award | A | Stock option (right to buy) | 1,000,000 | 3.97 | 3.97M | 1,000,000 | — | ↗ |
| 2006-10-25 | Fischer Laurent | Director | A-Award | A | Right to Buy (Stock Option) | 25,000 | 6.50 | 162.5K | 25,000 | — | ↗ |
| 2006-01-24 | LIMBER JOSEPH M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 8.27 | 124.1K | 15,000 | — | ↗ |
| 2006-01-24 | LERNER IRWIN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 8.27 | 124.1K | 15,000 | — | ↗ |
| 2006-01-24 | FLETCHER R JOHN | Director | A-Award | A | Stock options (right to buy) | 15,000 | 8.27 | 124.1K | 15,000 | — | ↗ |
| 2005-09-15 | FLETCHER R JOHN | Director | S-Sale | D | Common Stock | 5,000 | 9.86 | 49.3K | 545,000 | — | ↗ |
| 2005-08-29 | FLETCHER R JOHN | Director | J-Other | A | Common Stock | 16,521 | 0.00 | — | 66,521 | — | ↗ |
| 2005-08-25 | GREAT POINT PARTNERS LLC | 10% Owner | S-Sale | D | Common Stock | 66,692 | 10.28 | 685.4K | 1,012,308 | — | ↗ |
| 2005-08-24 | GREAT POINT PARTNERS LLC | 10% Owner | S-Sale | D | Common Stock | 105,500 | 9.60 | 1.01M | 1,079,000 | — | ↗ |
| 2005-08-23 | GREAT POINT PARTNERS LLC | 10% Owner | S-Sale | D | Common Stock | 35,500 | 9.56 | 339.5K | 1,184,500 | — | ↗ |
| 2005-08-22 | GREAT POINT PARTNERS LLC | 10% Owner | S-Sale | D | Common Stock | 100,000 | 11.18 | 1.12M | 1,220,000 | — | ↗ |
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PANC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
